Novartis News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

31.10.23	FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade (GlobeNewswire)
30.10.23	Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN) (GlobeNewswire)
24.10.23	Novartis delivers 12% sales and 21% core operating income growth from continuing operations (in cc¹). Executes Sandoz spin-off, achieves important innovation milestones, and raises FY 2023 guidance (GlobeNewswire)
24.10.23	Novartis steigert Umsatz um 12% und operatives Kernergebnis um 21% (fortzuführende Geschäftsbereiche, kWk¹). Sandoz abgespalten, wichtige Innovationsmeilensteine erreicht und Prognose 2023 erhöht (GlobeNewswire)
23.10.23	Novartis Pluvicto™ shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer in the pre-taxane settin (GlobeNewswire)
20.10.23	Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer (GlobeNewswire)
05.10.23	Novartis to present new oncology data at ESMO 2023 demonstrating practice-changing innovation in advanced prostate and early breast cancer (GlobeNewswire)
04.10.23	Novartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines company (GlobeNewswire)
02.10.23	Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN) (GlobeNewswire)
29.09.23	Novartis completes divestment of ‘front of eye’ ophthalmology assets (GlobeNewswire)
26.09.23	Sandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in Europe (GlobeNewswire)
25.09.23	Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors ( (GlobeNewswire)
25.09.23	Novartis confirms Sandoz Spin-off for October 4, 2023 (GlobeNewswire)
18.09.23	Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab (GlobeNewswire)
15.09.23	Novartis shareholders approve the proposed 100% Spin-off of Sandoz (GlobeNewswire)
15.09.23	Aktionärinnen und Aktionäre von Novartis stimmen dem geplanten 100% igen Spin-off von Sandoz zu (GlobeNewswire)
11.09.23	Sandoz announces exclusive deal to commercialize biosimilar ustekinumab, further reinforcing growing pipeline and immunology patient offering (GlobeNewswire)
06.09.23	Novartis appoints Patrick Horber, M.D., President, International as Marie-France Tschudin, President, Innovative Medicines International and Chief Commercial Officer, steps down from the Executive Com (GlobeNewswire)
06.09.23	Novartis ernennt Dr. Patrick Horber zum President, International, da Marie-France Tschudin, President, Innovative Medicines International und Chief Commercial Officer, aus der Geschäftsleitung von Nov (GlobeNewswire)
05.09.23	Sandoz veröffentlicht Nachtrag zum Kotierungsprospekt, einschliesslich Finanzabschluss von Sandoz für das 1. Halbjahr 2023 (GlobeNewswire)
05.09.23	Sandoz publishes supplement to Listing Prospectus including Sandoz H1 2023 financial statements (GlobeNewswire)
28.08.23	Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years (GlobeNewswire)
28.08.23	Sandoz completes acquisition of leading antifungal agent Mycamine® from Astellas, reinforcing leading global anti-infectives portfolio (GlobeNewswire)
25.08.23	Sandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis (GlobeNewswire)
18.08.23	Novartis issues EGM Invitation and Shareholder Information Brochure. Sandoz publishes Listing Prospectus ahead of proposed Spin-off vote (GlobeNewswire)
18.08.23	Novartis publiziert Einladung und Aktionärsbroschüre zur ausserordentlichen Generalversammlung. Sandoz veröffentlicht den Kotierungsprospekt im Vorfeld der Abstimmung zum vorgeschlagenen Spin-off (GlobeNewswire)
15.08.23	Sandoz announces positive results from Mylight Phase lll study for biosimilar aflibercept (GlobeNewswire)
11.08.23	Novartis Completes Acquisition of Chinook Therapeutics (GlobeNewswire)
09.08.23	Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticaria (GlobeNewswire)
24.07.23	Sandoz receives positive CHMP opinion for multiple sclerosis biosimilar natalizumab (GlobeNewswire)
20.07.23	Sandoz announces plans to build a Biosimilar Technical Development Center in Slovenia to support future growth of biosimilar pipeline (GlobeNewswire)
18.07.23	Novartis erzielt kräftige Umsatz- und Margensteigerungen und erhöht die Prognose. Aktienrückkaufprogramm von USD 15 Milliarden angekündigt; der Verwaltungsrat unterstützt den Spin-off von Sandoz[1],[2 (GlobeNewswire)
18.07.23	Novartis delivers strong sales growth, robust margin expansion and raises guidance. Announces USD 15 billion share buyback and Board endorses Sandoz spin-off[1],[2] (GlobeNewswire)
07.07.23	Novartis will appeal to U.S. Court of Appeals to uphold validity of Entresto® combination patent; maintains 2023 guidance and mid-term outlook (GlobeNewswire)
01.07.23	Sandoz to launch Hyrimoz® (adalimumab-adaz) high-concentration formulation, marking Sandoz entrance into US immunology space (GlobeNewswire)
30.06.23	Novartis signs agreement to divest ‘front of eye’ ophthalmology assets in line with focused strategy (GlobeNewswire)
15.06.23	Sandoz introduces Act4Biosimilars Action Plan to accelerate patient access to biosimilar medicines (GlobeNewswire)
12.06.23	Novartis bolsters innovative medicines strategy and renal pipeline with agreement to acquire Chinook Therapeutics for USD 3.2bn upfront (USD 40 / share) (GlobeNewswire)
08.06.23	Sandoz presents compelling investment proposition as standalone company at Capital Markets Day (GlobeNewswire)
02.06.23	Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups (GlobeNewswire)
01.06.23	Sandoz plans move to new central Basel headquarters by mid-2024, following proposed spin-off as standalone company (GlobeNewswire)
25.05.23	Sandoz Marketing Authorization Applications for proposed biosimilar denosumab accepted by EMA (GlobeNewswire)
15.05.23	New Sandoz Board of Directors appointed (GlobeNewswire)
11.05.23	Novartis to feature new PNH and CML scientific data from broad hematology portfolio at European Hematology Association Annual Meeting (GlobeNewswire)
09.05.23	Sandoz strengthens pipeline expansion through partnership to develop and manufacture multiple biosimilars (GlobeNewswire)
04.05.23	Sandoz to exclusively commercialize six products in the US, reinforcing global leadership position in off-patent medicines (GlobeNewswire)
26.04.23	Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa (GlobeNewswire)
26.04.23	Novartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO (GlobeNewswire)
26.04.23	Novartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naïve PNH patients (GlobeNewswire)
25.04.23	Novartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidance (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

18:01		Dow Jones aktuell: Dow Jones notiert am Mittag im Plus
18:01		Börse New York in Grün: So steht der NASDAQ 100 aktuell
17:58		Minuszeichen in London: FTSE 100 schwächelt zum Ende des Freitagshandels
17:58		Handel in Europa: STOXX 50 schliesst im Minus
17:58		Schwacher Handel: SMI schliesst mit Verlusten
17:58		Verluste in Europa: Euro STOXX 50 letztendlich leichter
17:58		SPI-Handel aktuell: SPI zum Handelsende leichter